George Yancopoulos, EVP, CSO, & President Regn Res Labs at REGENERON PHARMACEUTICALS INC (REGN), sold 90,044 shares at $24.76 ($2.2M) on 2007-04-16, disclosed to the SEC on 2007-04-17.
Scheduled sale ($2.2M) by EVP, CSO, & President Regn Res Labs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.60 | 38,835 | $955K | 43.2% |
| 2 | $24.60 | 20,326 | $500K | 22.6% |
| 3 | $24.40 | 1,600 | $39K | 1.8% |
| 4 | $24.41 | 200 | $5K | 0.2% |
| 5 | $24.42 | 2,300 | $56K | 2.5% |
| 6 | $24.43 | 1,000 |
| $24K |
| 1.1% |
| 7 | $24.44 | 1,400 | $34K | 1.5% |
| 8 | $24.45 | 1,400 | $34K | 1.5% |
| 9 | $24.47 | 300 | $7K | 0.3% |
| 10 | $24.48 | 500 | $12K | 0.6% |
| 11 | $24.49 | 200 | $5K | 0.2% |
| 12 | $24.50 | 300 | $7K | 0.3% |
| 13 | $24.51 | 1,600 | $39K | 1.8% |
| 14 | $24.52 | 1,100 | $27K | 1.2% |
| 15 | $24.53 | 761 | $19K | 0.8% |
| 16 | $24.54 | 9,039 | $222K | 10.0% |
| 17 | $24.55 | 1,983 | $49K | 2.2% |
| 18 | $24.63 | 100 | $2K | 0.1% |
| 19 | $24.64 | 200 | $5K | 0.2% |
| 20 | $24.67 | 900 | $22K | 1.0% |
| 21 | $24.68 | 300 | $7K | 0.3% |
| 22 | $24.69 | 1,000 | $25K | 1.1% |
| 23 | $24.70 | 1,300 | $32K | 1.5% |
| 24 | $24.71 | 1,900 | $47K | 2.1% |
| 25 | $24.72 | 100 | $2K | 0.1% |
| 26 | $24.73 | 700 | $17K | 0.8% |
| 27 | $24.75 | 500 | $12K | 0.6% |
| 28 | $24.76 | 100 | $2K | 0.1% |
| 29 | $24.77 | 100 | $2K | 0.1% |
| Total | $24.58 avg | 90,044 | $2.2M | 100% |
| Filing → |
| REGN | SELL | 2024-01-04 | $15.2M | — | Filing → |
| REGN | SELL | 2023-03-27 | $5.0M | — | Filing → |
| REGN | SELL | 2023-02-08 | $21.1M | — | Filing → |